Skip to Main content Skip to Navigation

Conception, synthèse et évaluation d'antagonistes des récepteurs A2A

Abstract : Alzheimer’s disease (AD) is the most prevalent form of dementia in the aged population. So far, there is no way to halt or slow-down AD. Therefore, there is a constant need of developing novel therapeutic strategies.In recent years, adenosine A2A receptor (A2AR) has attracted a growing interest since it has been proved that this receptor is over-expressed during AD. Also, epidemiological studies showed that people consuming regularly caffeine-based beverages over a lifetime are substantially less likely to develop this disease. Indeed, A2AR antagonists improve memory performance as it reduces β-amyloid deposits and Tau-phosphorylation.Though several antagonists have been developed for the treatment of neurodegenerative diseases, current research efforts are focus on developing new antagonists with relevant ADME properties and a better efficacy. Based on a molecular modeling-guided design, we synthesised new A2AR antagonists with benzoxazole and quinazoline as central scaffold. Three molecules were selected and will be subject to evaluation on animal’s model.
Document type :
Complete list of metadatas

Cited literature [149 references]  Display  Hide  Download
Contributor : Abes Star :  Contact
Submitted on : Friday, February 23, 2018 - 3:27:05 PM
Last modification on : Wednesday, October 14, 2020 - 4:10:42 AM
Long-term archiving on: : Friday, May 25, 2018 - 4:36:27 AM


Version validated by the jury (STAR)


  • HAL Id : tel-01716340, version 1



Romain Duroux. Conception, synthèse et évaluation d'antagonistes des récepteurs A2A. Médecine humaine et pathologie. Université du Droit et de la Santé - Lille II, 2017. Français. ⟨NNT : 2017LIL2S015⟩. ⟨tel-01716340⟩



Record views


Files downloads